Interv Akut Kardiol. 2017;16(2):63-68 | DOI: 10.36290/kar.2017.037
Pulmonary arterial hypertension – diagnosis and treatment
- 1. interní klinika – kardiologická, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc
Pulmonary arterial hypertension (PAH) is a disease of the small pulmonary arteries that is characterized by vascular proliferation and
remodeling. It results in a progressive increase in pulmonary vascular resistance and, ultimately, right ventricular failure and death. Despite
recent major improvements in symptomatic treatments, no current treatment cures this devastating condition. However, during the past
25 years, treatment options for patients with the disease have evolved to help prolong their survival and improve their quality of life.
Keywords: pulmonary arterial hypertension, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, prostacyclin analogues, lung transplant, atrial septostomy
Received: February 15, 2018; Accepted: February 20, 2018; Prepublished online: February 20, 2018; Published: May 1, 2017 Show citation
References
- Gali? N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37(1): 67-119. doi: 10.1093/eurheartj/ehv317.
Go to original source... 
Go to PubMed... - Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172. Go to original source... Go to PubMed...
- Rich S. The 6-minute walk test as a primary endpoint in clinical trials for pulmonary hypertension. J Am Coll Cardiol 2012; 60: 1202-1203. Go to original source... Go to PubMed...
- Farber HW. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole? Circulation 2012; 126: 258-260. Go to original source... Go to PubMed...
- Fritz JS, Blair C, Oudiz RJ, et al. Baseline and follow-up six minute walk distance and BNP predict 2-year mortality in pulmonary arterial hypertension. Chest 2013; 143: 315-323. Go to original source... Go to PubMed...
- Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163. Go to original source... Go to PubMed...
- Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension?: a meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192-1201. Go to original source... Go to PubMed...
- Gali? N, Corris PA, Frost A. Updated Treatment Algorithm of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2013; 62: D60-D72. Go to original source... Go to PubMed...
- Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369: 809-818. Go to original source... Go to PubMed...
- Ghofrani HA, Gali? N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013, 25; 369(4): 319-329. Go to original source... Go to PubMed...
- Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788. Go to original source... Go to PubMed...
- Gali? N, Barber? JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(9): 834-844. Go to original source... Go to PubMed...